Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix CEO to Participate in CES 2018 Panel on Opioid Crisis
WALTHAM, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D ., Ph.D., President and Chief Executive Officer, will participate in a panel at the Digital Health Summit at CES 2018.  The panel, “The Vicious Spiral: How Will the Opioid
View HTML
Toggle Summary NeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase Conferences
WALTHAM, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the 10 th Annual Biotech Showcase 2018 Conference at the Hilton San Francisco Union Square on Monday,
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell ® device usability by improving performance for users that maintain an active
View HTML
Toggle Summary NeuroMetrix Closes $3.5 Million Equity Offering
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per
View HTML
Toggle Summary NeuroMetrix Reports Q3 2017 Financial Results
Overall revenue of $3.5M is up 5% year-over-year Quell shipments of 15.6K devices are up 29% year-over-year Quell shipments of 28.7K electrode reorders are up 99% year-over-year Capital structure was simplified with 86% of outstanding warrants retired WALTHAM, Mass.
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19,
View HTML
Toggle Summary NeuroMetrix Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12th, 2017
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO) today announced it will be a presenting company at the 19 th  Annual Rodman & Renshaw Global Investment Conference, sponsored by H. C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York
View HTML
Toggle Summary Two Studies Derived from Quell Health Cloud to be Presented at Upcoming PAINWeek National Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the upcoming PAINWeek national conference to be held in Las Vegas, NV, September 5-9. Both studies leveraged the Quell ® Health Cloud, which connects with the Quell
View HTML
Toggle Summary NeuroMetrix Teams Up with U.S. Pain Foundation to Raise Awareness of Chronic Pain
WALTHAM, Mass. --(BUSINESS WIRE)-- In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. (Nasdaq: NURO) is partnering with the U.S. Pain Foundation , a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Automated Control of Quell Therapy During Sleep
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell ® device automatically modulates therapeutic neurostimulation based on the user's
View HTML